William Blair initiated coverage on shares of Tabula Rasa HealthCare (NASDAQ:TRHC) in a research report report published on Monday, MarketBeat reports. The firm issued an outperform rating on the stock.

A number of other equities analysts have also commented on TRHC. UBS raised their price objective on shares of Tabula Rasa HealthCare from $18.00 to $25.00 and gave the company a buy rating in a research report on Wednesday, August 30th. Wells Fargo & Company lowered shares of Tabula Rasa HealthCare from an outperform rating to a market perform rating and raised their price objective for the company from $17.00 to $21.00 in a research report on Thursday, September 7th. Piper Jaffray Companies restated an overweight rating and issued a $29.00 price objective (up from $20.00) on shares of Tabula Rasa HealthCare in a research report on Wednesday, September 20th. ValuEngine upgraded shares of Tabula Rasa HealthCare from a sell rating to a hold rating in a research report on Saturday, September 30th. Finally, Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a hold rating to a strong-buy rating and set a $31.00 price objective for the company in a research report on Wednesday, October 11th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Tabula Rasa HealthCare has a consensus rating of Buy and an average target price of $28.25.

Shares of Tabula Rasa HealthCare (NASDAQ TRHC) opened at $28.13 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.66. Tabula Rasa HealthCare has a 1-year low of $11.59 and a 1-year high of $36.80.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Monday, November 6th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. Tabula Rasa HealthCare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The firm had revenue of $33.27 million during the quarter, compared to the consensus estimate of $31.76 million. During the same quarter last year, the company earned $0.06 earnings per share. The company’s revenue was up 37.6% on a year-over-year basis. equities research analysts expect that Tabula Rasa HealthCare will post 0.05 earnings per share for the current fiscal year.

In other Tabula Rasa HealthCare news, insider Orsula V. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $26.68, for a total transaction of $213,440.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gordon Tunstall sold 15,000 shares of Tabula Rasa HealthCare stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $25.85, for a total transaction of $387,750.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,099,180 shares of company stock valued at $28,435,203. 45.80% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the business. Hood River Capital Management LLC lifted its position in Tabula Rasa HealthCare by 7.5% during the second quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock valued at $12,420,000 after purchasing an additional 57,724 shares during the last quarter. Vanguard Group Inc. lifted its position in Tabula Rasa HealthCare by 13.4% during the second quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock valued at $3,566,000 after purchasing an additional 27,997 shares during the last quarter. Boston Partners lifted its position in Tabula Rasa HealthCare by 17.1% during the second quarter. Boston Partners now owns 235,180 shares of the company’s stock valued at $3,540,000 after purchasing an additional 34,360 shares during the last quarter. Pier Capital LLC bought a new stake in Tabula Rasa HealthCare during the third quarter valued at approximately $4,151,000. Finally, Wasatch Advisors Inc. purchased a new position in shares of Tabula Rasa HealthCare during the third quarter worth approximately $4,047,000. Institutional investors and hedge funds own 31.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/william-blair-begins-coverage-on-tabula-rasa-healthcare-trhc/1765249.html.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.